Author

Aaron Goldman

Harvard Medical School - Cited by 1,495 - Cancer Biology

Biography

Aaron Goldman working as Director of Drug Resistance, Harvard Medical School, Cancer Immunology, DFCI/HCC, USA. His research is focused on understanding the diversity of cells that comprise cancer, collectively termed ‘intratumor heterogeneity’, and its role in therapy failure using interdisciplinary strategies that interrogate evolutionary biology. He has junior faculty position at Harvard Medical School and MIT Division of Health Sciences and Technology. Aaron Goldman have been supported by the North East Spin Odyssey Foundation, American Cancer Society, Breast Cancer Alliance, and the Biomedical Research Institute to develop cross-collaborative projects that resulted in multiple international patents.
Title
Cited by
Year
Advances in understanding the role of P-gp in doxorubicin resistance: Molecular pathways, therapeutic strategies, and prospects
S Mirzaei, MH Gholami, F Hashemi, A Zabolian, MV Farahani, ...Drug Discovery Today 27 (2), 436-455, 2022202
61
2022
Targeting tumor phenotypic plasticity and metabolic remodeling in adaptive cross-drug tolerance
A Goldman, S Khiste, E Freinkman, A Dhawan, B Majumder, J Mondal, ...Science signaling 12 (595), eaas8779, 2019201
48
2019
Insights into exchange factor directly activated by cAMP (EPAC) as potential target for cancer treatment
N Kumar, P Prasad, E Jash, M Saini, A Husain, A Goldman, S SehrawatMolecular and cellular biochemistry 447 (1-2), 77-92, 2018201
32
2018
Engineering in medicine to address the challenge of cancer drug resistance: from micro-and nanotechnologies to computational and mathematical modeling
M Craig, AL Jenner, B Namgung, LP Lee, A GoldmanChemical Reviews 121 (6), 3352-3389, 2020202
31
2020
Cooperative adaptation to therapy (CAT) confers resistance in heterogeneous non-small cell lung cancer
M Craig, K Kaveh, A Woosley, AS Brown, D Goldman, E Eton, RM Mehta, ...PLoS computational biology 15 (8), e1007278, 2019201
21
2019
Systems, methods, and devices for componentization, modification, and management of creative assets for diverse advertising platform environments
A Goldman, DRH Bougourd, JM Dougherty, MJ Perreux, CB Hartnett, ...US Patent 11,348,142, 222
20
2022
Perspectives on the role of brain cellular players in cancer-associated brain metastasis: translational approach to understand molecular mechanism of tumor progression
M Raza, P Prasad, P Gupta, N Kumar, T Sharma, M Rana, A Goldman, ...Cancer and Metastasis Reviews 37, 791-804, 202
18
2018
Perspective on nanochannels as cellular mediators in different disease conditions
E Jash, P Prasad, N Kumar, T Sharma, A Goldman, S SehrawatCell Communication and Signaling 16 (1), 1-9, 202
18
2018
cAMP regulated EPAC1 supports microvascular density, angiogenic and metastatic properties in a model of triple negative breast cancer
N Kumar, P Prasad, E Jash, S Jayasundar, I Singh, N Alam, N Murmu, ...Carcinogenesis 39 (10), 1245-1253, 2018201
16
2018
Nanoengineered disruption of heat shock protein 90 targets drug-induced resistance and relieves natural killer cell suppression in breast cancer
Nanoengineered disruption of heat shock protein 0 targets drug-induced resistance and relieves natural killer cell suppression in breast cancerM Smalley, SK Natarajan, J Mondal, D Best, D Goldman, B Shanthappa, ...Cancer research 80 (23), 5355-5366, 2020202
9
2020
Nanotherapeutic approaches to overcome distinct drug resistance barriers in models of breast cancer
T Saha, J Mondal, S Khiste, H Lusic, ZW Hu, R Jayabalan, KJ Hodgetts, ...Nanophotonics 10 (12), 3063-3073, 2021202
9
2021
Agent-based computational modeling of glioblastoma predicts that stromal density is central to oncolytic virus efficacy
AL Jenner, M Smalley, D Goldman, WF Goins, CS Cobbs, RB Puchalski, ...Iscience 25 (6), 104395, 2022202
7
2022
Systems biology informed neural networks (SBINN) predict response and novel combinations for PD-1 checkpoint blockade
M Przedborski, M Smalley, S Thiyagarajan, A Goldman, M KohandelCommunications Biology 4 (1), 877, 2021202
6
2021
Boosting natural killer cell therapies in glioblastoma multiforme using supramolecular cationic inhibitors of heat shock protein 90
T Saha, AA van Vliet, C Cui, JJ Macias, A Kulkarni, LN Pham, S Lawler, ...Frontiers in Molecular Biosciences 8, 74443, 2021202
5
2021
Integrating systems biology and an ex vivo human tumor model elucidates PD-1 blockade response dynamics
M Smalley, M Przedborski, S Thiyagarajan, M Pellowe, A Verma, ...Iscience 2 (6), 2020202
3
2020
A computationally inspired in-vivo approach identifies a link between amygdalar transcriptional heterogeneity, socialization and anxiety
A Goldman, JL Smalley, M Mistry, H Krenzlin, H Zhang, A Dhawan, ...Translational Psychiatry 9 (1), 6, 2019201
3
2019
A call to arms: Unifying the fight against resistance
A Kaushansky, L Hedstrom, A Goldman, J Singh, PL Yang, PK Rathod, ...Science signaling 11 (55), eaav0442, 2018201
3
2018
Translational efficacy of oncolytic HSV-1 in glioblastoma using a human autologous ex vivo platform, CANscript™
Translational efficacy of oncolytic HSV- in glioblastoma using a human autologous ex vivo platform, CANscript™M Smalley, V Kapoor, D Best, C Passaro, MO Nowicki, SK Saha, K Prasad, ...Cancer Research 79 (3_Supplement), 5009-5009, 20920
1
2019
Drug-induced resistance: nipping it in the ‘budding’
A GoldmanOncotarget 9 (89), 35873, 20820
1
2018
Nonuniform T-cell infiltration induced by PD-1 checkpoint blockade, ex vivo, predicts distinct clinical response
Nonuniform T-cell infiltration induced by PD- checkpoint blockade, ex vivo, predicts distinct clinical responseM Smalley, B Shanthappa, H Gertje, M Lawson, B Ulaganathan, ...Cancer Research 78 (3_Supplement), 705-705, 20820
1
2018

Referred From: https://scholar.google.com/citations?user=oOy8EeUAAAAJ&hl=en

Cited by
Citations 1495
h-index 21
i10-index 30
Recommended Journals
Open Access Journals